Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study-Reference-Cited by-同舟云学术

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Published:2017-04 Issue:10080 Volume:389 Page:1699-1709
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Feagan Brian G,Sandborn William J,D'Haens Geert,Panés Julián,Kaser Arthur,Ferrante Marc,Louis Edouard,Franchimont Denis,Dewit Olivier,Seidler Ursula,Kim Kyung-Jo,Neurath Markus F,Schreiber Stefan,Scholl Paul,Pamulapati Chandrasena,Lalovic Bojan,Visvanathan Sudha,Padula Steven J,Herichova Ivona,Soaita Adina,Hall David B,Böcher Wulf O

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. Crohn's disease;Baumgart;Lancet,2012

2. Certolizumab pegol for the treatment of Crohn's disease;Sandborn;N Engl J Med,2007

3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial;Targan;Gastroenterology,2007

4. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials;Peyrin-Biroulet;Clin Gastro Hepatol,2008

5. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys;Gordon;Eur J Gastroenterol Hepatol,2015

Cited by 382 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins;The Korean Journal of Gastroenterology;2024-08-25

3. Integration of Gut Mycobiota and Oxidative Stress to Decipher the Roles of C-Type Lectin Receptors in Inflammatory Bowel Diseases;Immunological Investigations;2024-08-08

4. Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE);Gastrointestinal Disorders;2024-07-07

5. Network meta‐analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-06-11